To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.
The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].
The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.
Click on each trial for more detail of findings and quality.
December 2013
Kidney transplantation
A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients.
Bloom RD, Trofe-Clark J, et al. Clinical Transplantation 2013;27(6):E685-93
Randomized controlled trial comparing hand-assisted retroperitoneoscopic versus standard laparoscopic donor nephrectomy.
Dols LF, Kok NF, et al. Transplantation 2014 Jan 27;97(2):161-7
Effects of transcutaneous electrical nerve stimulation on pain, walking function, respiratory muscle strength and vital capacity in kidney donors: a protocol of a randomized controlled trial.
Galli T, Chiavegato L, et al. BMC Nephrology 2013; 14: 7.
Comparison of the effects of normal saline versus plasmalyte on acid-base balance during living donor kidney transplantation using the stewart and base excess methods.
Kim SY, Huh KH, et al. Transplantation Proceedings 2013; 45(6): 2191-2196.
Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients.
Min SI, Ha J, et al. Nephrology Dialysis Transplantation 2013 Dec;28(12):3110-9.
Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial.
Murbraech K, Holdaas H, et al. Transplantation 2014;97(2):184-8
Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.
Rostaing L, Vincenti F, et al. American Journal of Transplantation 2013; 13(11): 2875-2883.
Rapamycin induces ILT3ILT4 dendritic cells promoting a new immunoregulatory pathway.
Stallone G, Pontrelli P, et al. Kidney International 2013; 85(4): 888-897.
Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
Welberry Smith MP, Cherukuri A, et al. Transplantation 2013;96(12):1082-8
Lung transplantation
A randomized controlled trial comparing health and quality of life of lung transplant recipients following nurse and computer-based triage utilizing home spirometry monitoring.
Finkelstein SM, Lindgren BR, et al. Telemedicine Journal and E-Health 2013;19(12):897-903